Table 1.
Virologic and Immunologic Measures of Patients Taking Combination Antiretroviral Therapy (cART) Incorporating Raltegravir (RAL) and Non–RAL-cART Control Patients at Entry
| Measure | RAL-cART (n = 15) | Non–RAL-cART (n = 15) |
|---|---|---|
| Plasma VL (copies/mL) | 5.2 ± 5.3 log10 | 4.69 ± 4.42 log10 |
| Mean absolute CD4 (cells/µL) | 360.3 ± 201.5 | 376.8 ± 196.64 |
| Mean CD4+CD38+HLA-DR+ (%) | 7.1 ± 3.5 | 6.7 ± 2.9 |
| Mean CD8+CD38+HLA-DR+ (%) | 17.6 ± 7.6 | 18.1 ± 5.6 |
| Mean CD4+PD1+ (%) | 19.2 ± 5.5 | 16.6 ± 9.5 |
| Mean CD8+PD1+ (%) | 24.2. ± 8.6 | 26.8 ± 10.8 |
| Mean plasma sCD14 (pg/mL) | 1 268 000 ± 346 634 | 1 129 845 ± 308069.5 |
| Mean plasma LPS (pg/mL) | 221.3 ± 51.7 | 195.0 ± 38.1 |
Abbreviations: LPS, lipopolysaccharide; PD1, programmed death receptor 1; RAL-cART, combination antiretroviral therapy incorporating raltegravir; sCD14, soluble CD14; VL, viral load.